Science and Enterprise

Tag: biomarkers

  • Trial Crowdsources Lung Cancer Biomarker Screening

    22 August 2014. A clinical trial at University of Colorado Cancer Center in Aurora is recruiting participants through an online campaign to find people with lung cancer that meet a specific genetic profile who would most likely respond to the drug being tested. The study is led by Ross Camidge, director of the center’s thoracic…

  • Challenge Seeks Biomarkers for Neuropathic Pain

    1 August 2014. A new challenge on InnoCentive is seeking biomarkers that help predict the effectiveness of pain-killing therapies for patients with neuropathic pain. The challenge requires a detailed written proposal due on 27 September 2014, with a payout of $25,000. Free registration is required to see the challenge details. InnoCentive in Waltham, Massachusetts conducts…

  • Spin-Off Company Developing Cardiac Drug Tests

    22 July 2014. A medical researcher at Coventry University in the U.K. is spinning-off a new company to commercialize her research on cardiac drug toxicity for screening new therapies for dangerous side effects before testing on patients. Helen Maddock, a lecturer in cardiovascular physiology and pharmacology, is starting InoCardia to provide this service to pharmaceutical…

  • U.K. Public-Private Partnership to Attack Dementia

    20 June 2014. Medical Research Council, a science funding agency in the U.K., organized a consortium of academic and industry researchers to better detect, prevent, and treat dementia. The council and six industry partners plan to spend £16 million ($US 27.25 million) on the U.K. Dementias Research Platform that includes studies involving some 2 million…

  • EMD Serono, Pfizer, Broad Institute Partner on Lupus Markers

    1 April 2014. EMD Serono, a subsidiary of the pharmaceutical company Merck in Rockland, Massachusetts, is joining with the drug maker Pfizer and Broad Institute of Harvard and MIT to identify genomic biomarkers of two types of lupus. The research is funded by EMD Serono and Pfizer, but financial aspects of the agreement were not…

  • Investments Added to Breakout Labs Life Science Seed Grants

    26 March 2014. NetScientific in Cambridge, U.K. is adding investment funds for qualified life science enterprises taking part in Breakout Labs to help them advance beyond the initial start-up phase. Under the deal, Breakout Labs portfolio companies fitting into NetScientific’s investment priorities will qualify for $250,000 in follow-on investment beyond Breakout Labs’ $350,000 in seed…

  • Blood Biomarker Measured in Hockey Player Concussions

    14 March 2014. Researchers at Quanterix Corp. in Lexington, Massachusetts, and universities in Sweden, tested the company’s method for detecting and measuring tau protein as an indicator of concussion in the blood of professional hockey players. The team led by Pashtun Shahim at University of Gothenburg, with colleagues at Quanterix, Sahlgrenska University Hospital, and University College London published their findings…

  • NIH, Pharmas, Non-Profits Partner on Molecular Drug Targets

    4 February 2014. National Institutes of Health (NIH), with 10 pharmaceutical companies and 8 not-for-profit organizations, are collaborating on identification of targets at the molecular level for new drugs and diagnostics. The Accelerating Medicines Partnership — a five-year, $230 million initiative — is expected to focus on Alzheimer’s disease, type 2 diabetes, and the autoimmune disorders…

  • Diagnostics Developer, Mt. Sinai to Partner on Biomarkers

    Exosome Diagnostics and Mount Sinai medical center, both in New York, are collaborating on the discovery of genetic biomarkers to build diagnostics for inflammation, cancer, and other diseases. Financial aspects of the five-year agreement were not disclosed. Exosome Diagnostics develops diagnostics based on biomarkers derived from bodily fluids, such as blood, urine, plasma, serum, and…

  • Diagnostics Company Lands $12 Million Series B Funds

    Advanced Cell Diagnostics Inc., a genomic diagnostics developer in Hayward, California, secured $12 million in series B funding, the second round of venture financing after initial start up. New Leaf Venture Partners that specializes in health care technology investments led the round, joined by existing investor Morningside Ventures. Advanced Cell Diagnostics makes diagnostic tests that…